Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Covidien completed the spin-off of its pharmaceuticals business - its Mallinckrodt plc subsidiary - into a separate public company.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury